Krishna Institute of Medical Sciences Limited has entered into a strategic clinical collaboration through a Memorandum of Understanding (MoU) with Dakshayani Healthcare Services Private Limited, as disclosed under Regulation 30 on April 23, 2026. The partnership focuses on enhancing oncology care services and improving patient outcomes through a comprehensive non-commercial brand association agreement.

Partnership Structure and Strategic Focus

The collaboration represents a non-commercial brand association between KIMS and Dakshayani Healthcare Services Private Limited, also known as "Renova." Renova is described as a specialized oncology organization with proprietary clinical protocols and expertise in cancer research and academic supervision, with extensive experience in managing cancer centers across India. The partnership specifically emphasizes oncology care enhancement and patient outcome improvement.

Collaboration Framework and Patient Care Enhancement

Under this arrangement, both KIMS and Renova will collaborate on a mutual, non-commercial basis with a dedicated focus on patient outcomes. Renova will share its clinical expertise, knowledge, and best practices in oncology care with KIMS. The association is specifically designed to strengthen healthcare delivery standards, particularly in oncology services, while ensuring enhanced patient care outcomes through collaborative clinical protocols.

Strategic Benefits and Outcomes

The partnership creates comprehensive mutual benefits for both organizations while prioritizing patient care improvement. Renova will enhance its brand positioning through association with Krishna Institute of Medical Sciences, while KIMS will benefit from and foster the collaborative development of clinical protocols and treatment methodologies with Renova. This strategic alliance aims to advance oncology care standards and deliver superior patient outcomes.

Regulatory Compliance and Market Disclosure

The company has informed both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) about this strategic collaboration pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. The association is expected to contribute positively to the overall service quality, patient care outcomes, and reputation of the company in the healthcare sector. The official communication was signed by Dr. Nagajayanthi J R, Company Secretary and Compliance Officer, confirming the formal nature of this strategic partnership.

Krishna Institute of Medical Sciences has received an upgraded target price from HSBC, with the global brokerage maintaining its Buy recommendation while raising the price target to ₹780 from ₹750.

HSBC's Investment Thesis

The brokerage's positive outlook is anchored on several key factors expected to drive performance in Q4FY26. HSBC anticipates a steady quarter with particular strength from the recovery in elective procedures, which typically contribute significantly to healthcare providers' revenue streams.

Growth Drivers and Expansion Strategy

HSBC highlights the company's continued capital expenditure-led expansion as a key growth driver. This strategic approach involves investing in new facilities and upgrading existing infrastructure to enhance service delivery and market reach.

The brokerage expects the following positive developments:

• Pickup in elective procedures contributing to revenue growth
• Sustained expansion through strategic capital investments
• Maintained operational efficiency despite expansion costs

Operational Performance Outlook

While HSBC acknowledges potential challenges from new unit margin drag, the brokerage considers this impact manageable within the broader growth strategy. The firm maintains confidence in Krishna Institute of Medical Sciences' ability to sustain healthy operating performance despite the temporary margin pressure from newly established units.

The upgraded target price reflects HSBC's confidence in the healthcare provider's strategic positioning and operational resilience in the evolving healthcare landscape.